Name
*
First Name
Last Name
Email
*
example@example.com
What best describes your title?
*
MD/DO
RN/NP
PA
PharmD
Industry
N/A
Other
If MD/DO
interventional cardiology
clinical cardiology
endocrinology
nephrology
emergency medicine
critical care
primary care
N/A
If RN/NP
APP
ICU/cath lab
ward
clinic
academic
N/A
If PharmD
hospital/health system-based
community
academic
Where are you based?
EU/GB
Canada
United States
How did you FIRST hear about our tweetorials?
found it on Twitter searching in subject area
found it on twitter searching for CE/CME
found it on Twitter by following individual influencer
found it on Twitter by following institutional influencer
from LinkedIn
How many years have you been in practice?
How many patients do you typically see each month?
1. Which statement is NOT true?
*
Semaglutide 2.4mg may provide significant weight loss in those with obesity/overweight with or w/out IBT (intensive behavioral therapy) in those with or w/out T2DM.
In STEP-4, continued semaglutide 2.4mg use resulted in further weight loss compared to weight regain on cessation, suggesting longer term persistence with semaglutide may have benefit.
The GI side effect profile is of extended therapy with semaglutide 2.4mg is worse than usually expected with GLP-1RAs.
In STEP-3, semaglutide 2.4mg compared to placebo in addition to IBT & low calorie diet (8 weeks) showed significant weight loss (86.6% lost >5% weight, vs 47.6% with placebo)
2. If SGLT2i or TZDs were NOT an option, what is likely the best approach to use in early T2D after metformin?
*
GLP1-RA
Basal Insulin
SU
DPP4i
3. What percentage of patients lost at least 15% of their body weight in STEP1?
*
10
20
30
40
50
4. What was the main adverse effect from semaglutide 2.4mg
*
Nausea
Diarrhoea
Abdo pain
Gall stone
Skin reaction
5. In an analysis and projection from the CREDENCE Study canagliflozin 100mg when given to people with type 2 diabetes and heavy albuminuric chronic kidney disease. Treatment with canagliflozin 100mg delayed time to renal replacement therapy by?
*
5 years
10 years
15 years
20 years
6. What proportion of people treated with tirzepatide 15mg to achieve a 15% weight loss
*
7%
17%
27%
37%
7. Did you follow the entire tweetorial?
*
Yes
No
8. Did you find this to be an effective learning tool?
*
Yes
No
9. Will you refer colleagues to similar programs from @cardiomet_ce?
*
Yes
No
-
Month
-
Day
Year
2 digit month, 2 digit day, 4 digit year
Date
Claim Certificate
Should be Empty: